is recommended as a treatment option for men presenting with low risk (Gleason 3þ3) and some intermediate risk (Gleason 3þ4) prostate cancer. BRCA1 or 2 germline mutations have been implicated in prostate cancer and affected men are at higher risk for developing prostate cancer and for failure after localized therapy. It is unknown if germline BRCA1/2 mutations in AS candidacy are associated with more aggressive histologic grade, higher stage or other worse genetic alterations, such as RB1 and p53 deletions.
INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
is recommended as a treatment option for men presenting with low risk (Gleason 3þ3) and some intermediate risk (Gleason 3þ4) prostate cancer. BRCA1 or 2 germline mutations have been implicated in prostate cancer and affected men are at higher risk for developing prostate cancer and for failure after localized therapy. It is unknown if germline BRCA1/2 mutations in AS candidacy are associated with more aggressive histologic grade, higher stage or other worse genetic alterations, such as RB1 and p53 deletions.
METHODS: We analyzed sequencing data from 498 men who underwent radical prostatectomy from The Cancer Genome Atlas (TCGA) data set. The primary outcome was the difference in the proportions of AS candidates among subjects with BRCA homodeletions and non-homodeletions. Tests for differences in the proportions were conducted using Fisher's Exact Test. Equivalence tests for proportions of AS candidates were conducted using the two-one sided tests (TOST) method. As a secondary outcome we studied the associated coincident mutations in the men with BRCA1 and BRCA2 homodeletions.
RESULTS: Forty-one men (8%) of the cohort had homodeletion of BRCA1 or BRCA2. Ten men (2%) had complete loss of BRCA1 while 31 (6%) had loss of BRCA2. Rates of candidacy for AS based on histology and stage (defined as stage T2, Gleason 6) are not different between subjects with and without BRCA 1 or 2 homodeletions, within an equivalence margin of 10 percentage points. These findings are similar when the AS criteria are modified to add Gleason 3þ4 subjects. Fifty percent of men with organ confined (pT2), 3þ3 and 3þ4 prostate cancer with BRCA1 or BRCA2 homodeletions had concomitant RB1 deletions compared with 16.5% of the entire cohort (p[0.002). This was primarily driven by BRCA2 deletions co-occurrent with RB1 deletions (log OR: 2.4, p<0.001), both of which are in close proximity on the long arm of chromosome 13. Twenty-nine percent of men from this group had concomitant p53 deletions compared to 7.5% of the entire cohort (p[0.004).
CONCLUSIONS:: In the TCGA data set, men with prostate cancer and BRCA1 or BRCA2 homodeletions present with similar stage and grade tumors than men without these deletions. Despite having low or low intermediate grade histology, however, BRCA1 and BRCA2 deleted tumors are enriched with deletions in RB1 and TP53, both of which are associated with more aggressive phenotypes and treatment resistance.
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PD50-09 QUANTIFICATION OF THE IMPACT OF PATIENT PREFERENCES ON DECISION MAKING IN MEN WITH LOW-RISK PROSTATE CANCER
Zhiyu Qian*, Sylvia Lambrechts, Lorna Kwan, Christopher Saigal, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Patients diagnosed with low-risk prostate cancer face the choice between undergoing active treatments (AT) and active surveillance (AS). AUA recommends shared decision-making with attention to the personal preferences of patients in this context. However, little is known about the relative influence of patient preferences compared to other factors, such as physician recommendation, on treatment decisions. We aimed to characterize the impact of patient preferences in relation to other clinical factors in the decision-making process of low-risk prostate cancer patients.
METHODS: Patients with low-risk prostate cancer seen at UCLA Health were offered a decision aid that used conjoint analysis to quantify their personal preferences for relevant outcomes prior to consults. Quantified preferences were then studied via latent class analysis (LCA). An electronic chart review was conducted to record treatment decisions, physician recommendation, comorbidities, and other clinical parameters. The association of each factor in the decision-making process of patients was evaluated in univariate and multivariate analyses.
RESULTS: 80 low-risk prostate cancer patients were included in this analysis. After consultation, 46% chose AS, 30% chose AT, and 24% were undecided. Univariate analysis showed relationship status, physician recommendation, and physician type were associated with different treatment decisions. LCA identified 2 clusters of representative preference profiles, where Cluster 1 more strongly valued longevity than Cluster 2 and preferred AT to AS. Multivariate analysis showed patients were 10.3 times more likely to prefer AT if they received an AT recommendation from an urologist. Patients with normal BMIs were 4.3 times more likely to favor active treatment. The identified patient preference profile was not a significant predictor of treatment choice in the multivariate analysis.
CONCLUSIONS: The strongest impact that recommendations from urologists carry among all other factors in patient decision-making is consistent with prior literature. Cluster analysis revealed the existence of distinct preference profiles associated with respective treatment patterns. The insignificant impact of patient preference in treatment decision raises concerns of medical paternalism. However, same finding can be explained by physicians already incorporated patient preferences in their recommendations, leading to masking of effects. Future work is needed to clarify this finding.
